FORM PTO-1449 (Rev. 2-32)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. Serial No.

98-009-B1

09/658,315



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Rogers, et al.

Filing Date:

Group:

September 8, 2000

1653

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	US 2004/0120959	June 24, 2004	Karl Tryggvason, et al.			October 28, 2003
H			<u> </u>			I	

FOREIGN PATENT DOCUMENTS

		·	-OREIGN PATER		T T		Trans	lation
		- Alumbar	Date	Country	Class	Subclass	Yes	No
		Document Number	7-30-98	PCT			X	
AG	1.	WO 98-32457		BOT			x	
AG	2.	WO 99-31125	6-24-99	PCT		 		
AG		WO 99-26644	6-3-99	PCT			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

			OTHER DOCUMENTS (Including Addition, That,	4
			Mrug, et al., (1996), "Angiotensin II Facilitates Erythropoietin-mediated	proliferation of early erythrold
ĺ		A	Mrug, et al., (1996), "Angiotensin il Facilitates El Juli polosimonio	
ľ	AG	4.	progenitors", Vol. 88, page 646a.	
1			l b. commercial	

				\neg
- CANADAS D	/Anish Cunts/	DATE CONSIDERED	01/05/2007	
EXAMINER	/Anish Gupta/			
l				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

	1
Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office
NOV 0 8 2006	FION DISCLOSURE NT BY APPLICANT

Atty. Docket No.	Serial No.
98,009-B\	09/658,315

Applicant: Kathleen Rodgers, et al.

Filing Date: Sept 8, 2000

Group: 1653

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS						
	Document Number	Date	Name	Class	Subclass	Filing Date
	6 924 422	11-10-98	Rodgers, et al.			
1.						
2.	5,955,430				 	
3.	4,987,121	1-22-91	Baertschi, et al.			
4	5,482,924	1-9-96 .	Royet, et al.		·	<u> </u>
	5,015,629	5-14-91	diZerega, et al.			
	5,629,292	5-13-97	Rodgers, et al.			
	5,716,935	2-10-98	Rodgers, et al.			<u> </u>
	5,693,616	12-2-97	Krstenansky, et al.			
	5,188,828	2-23-93	Goldberg, et al.			
	5,541,158	7-30-93	Vance, et al.			
	5,032,507	7-16-91	Yu, et al.			
ļ <u>.</u>	5,104,653	4-14-92	Michalevicz, et al.			
		1. 5,834,432 2. 5,955,430 3. 4,987,121 4. 5,482,924 5. 5,015,629 6. 5,629,292 7. 5,716,935 8. 5,693,616 9. 5,188,828 10. 5,541,158 11. 5,032,507	Document Number Date 1. 5,834,432 11-10-98 2. 5,955,430 9-21-99 3. 4,987,121 1-22-91 4. 5,482,924 1-9-96 5. 5,015,629 5-14-91 6. 5,629,292 5-13-97 7. 5,716,935 2-10-98 8. 5,693,616 12-2-97 9. 5,188,828 2-23-93 10. 5,541,158 7-30-93 11. 5,032,507 7-16-91	Document Number Date Name 1. 5,834,432 11-10-98 Rodgers, et al. 2. 5,955,430 9-21-99 Rodgers, et al. 3. 4,987,121 1-22-91 Baertschi, et al. 4. 5,482,924 1-9-96 Royet, et al. 5. 5,015,629 5-14-91 diZerega, et al. 6. 5,629,292 5-13-97 Rodgers, et al. 7. 5,716,935 2-10-98 Rodgers, et al. 8. 5,693,616 12-2-97 Krstenansky, et al. 9. 5,188,828 2-23-93 Goldberg, et al. 10. 5,541,158 7-30-93 Vance, et al. 11. 5,032,507 7-16-91 Yu, et al. Michalevicz, et al.	Document Number Date Name Class 1. 5,834,432 11-10-98 Rodgers, et al. 2. 5,955,430 9-21-99 Rodgers, et al. 3. 4,987,121 1-22-91 Baertschi, et al. 4. 5,482,924 1-9-96 Royet, et al. 5. 5,015,629 5-14-91 diZerega, et al. 6. 5,629,292 5-13-97 Rodgers, et al. 7. 5,716,935 2-10-98 Rodgers, et al. 8. 5,693,616 12-2-97 Krstenansky, et al. 9. 5,188,828 2-23-93 Goldberg, et al. 10. 5,541,158 7-30-93 Vance, et al. 11. 5,032,507 7-16-91 Yu, et al. 11. 5,032,507 7-16-91 Yu, et al.	Document Number Date Name Class Subclass 1. 5,834,432 11-10-98 Rodgers, et al. 2. 5,955,430 9-21-99 Rodgers, et al. 3. 4,987,121 1-22-91 Baertschi, et al. 4. 5,482,924 1-9-96 Royet, et al. 5. 5,015,629 5-14-91 diZerega, et al. 6. 5,629,292 5-13-97 Rodgers, et al. 7. 5,716,935 2-10-98 Rodgers, et al. 8. 5,693,616 12-2-97 Krstenansky, et al. 9. 5,188,828 2-23-93 Goldberg, et al. 10. 5,541,158 7-30-93 Vance, et al. 11. 5,032,507 7-16-91 Yu, et al.

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
<u> </u>		Document Number	Date	Country	Class	Subclass	<u>Translation</u> Yes No
				PCT			X
3.0	13	WO 96/39164	12-12-96	PCI		 	177
AG		<u> </u>	3-30-95	PCT	1	ì	X
VI/	14.	WO 95/08565		200			X
-A -	15.	WO 95/08337	3-30-95	PCT			<u> </u>
AG				<u> </u>			

OTHER DOCUMENTS - including Author, Title, Date, Pertinent Pages, Etc.

		OTHER DOCUMENTS - Including Author	or, Title, Date, Pertinent Pages, Etc.			
AG	16. Kurt R. Reissmann, M.D., (1950), Blood, "Studies on the Mechanizm of Erythropoietic Stimulation in Parabiotic Rats During Hypoxia", 8: pp. 349-357.					
AG	AG 17. Allan Erslev, M.D., (1953), Blood, "Humoral Regulation of Red Cell Production", 8: pp. 349-357.					
AG	AG 18 Jerry L. Spivak, (1986), Int. J. Cell Cloning, "The Mechanism of Action of Erythropoietin", 4: pp. 139-166.					
AG	10.					
AC	19	K. Sawada, et al., (1987), The Journal of Clinical Invest Units and Demonstration of Specific Binding of Erythrop	tigtation, Inc., "Purification of Human Erythroid Colony-forming poietin", 80: pp 357-366.			
	<u> </u>	Olius www. Deliwisi.com of spring				
Ex	aminer	/Anish Gupta/	Date Considered 01/05/2007			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form PTO-1449 INFC STA	U.S. Department of Commerce Patent and Trademark Office ORMATION DISCLOSURE	Atty. Docket No. 98,009-B	Serial No. 09/658,315
-		Applicant: Kathleen Rodger	rs, et al.
		Filing Date: Sept 8, 20	000 Group: 1653

	OTHER DOCUMENTS - Including Author	, Title, Date, Pertinent Pages, Etc.			
20.		Repeated Whole Blood Donations on Serum Immunoreactive			
21.		ietin Levels in Uremic Nephric and Anephric Patients", 93: pp.			
Heinz W. Radtke, et al., (1979), Blood, "Serum Erythropoietin Concentration in Chronic Renal Failure: Relationship to Degree of Anemia and Excretory Renal Function" 54(4): pp. 877-884.					
Manju Chandra, M.D., et al., (1988), J. Pediatr., "Relation of Serum Erythropoietin Levels to Renal Excretory Function Evidence for Lowered Set Point for Erythropoietin Production in Chronic Renal Failure", 113: pp. 1015-1021.					
24.	Joseph W. Eschbach, M.D., et al., (1988), American Jour	nal of Kidney Diseases, "Recombinant Human Erythropoietin:			
25.	Satya P. Kunapuli, et al., (1987), Circulation Research, "I for the Presence of Its mRNA in Rat Heart" 60: pp. 786-7	Molecular Cloning of Human Angiotensinogen cDNA andEvidence 190.			
"Molecular Cloring of the Mouse Angiotensingen Gene", 2: pp. 240-248.					
27.	Ryoichiro Kagevama, et al., (1984), Biochemistry, "Primary Structure of Human Preangiotensinogen Deduced from the				
28.	Hiroaki Ohkubo, et al., (1983), Biochemistry, "Cloning and Sequence Analysis of cDNA for Rat Angiotensinogen", 80: pp. 2196-2200.				
29.	Dinna N. Cruz, M.D., et al., (1996), American Journal of Kidney Diseases, "Angiotensin-Converting Enzyme Inhibitor Therapy in Chronic Hemodialysis Patients: Any Evidence of Erythropoietin Resistance?", 28(4): pp. 535-540.				
30.	of Anemia in Chronic Hemodialysis Patients", 26: pp. 2				
31.	Anne B. Gould, et al., (1980), J. Lab. Clin. Med., "Inter 523-534.	relation of the Renin System and Erythropoietin in Rats", 96: pp.			
32.	Transplantation", 56: pp. 217-219.	Beneficial Effect of Enalapril on Erythrocytosis After Renal			
33.	71: pp. 194-197.	"Does Angiotensin Play a Role in Human Fetal Erythropoiesis?",			
34.	B.I. Shand, et al., (1995), Journal of Human Hypertens: Elderly Patients with Essential Hypertension: A Pilot S	ion, "Effect of Losartan on Haematology and Haemorheology in tudy", 9: pp. 233-235.			
35.	Erythrocytosis", 46: pp. 1397-1403.	Erythropoiesis After Withdrawal of Enalapril in Post-Transplant			
AG 36.	R.S. Gaston, et al., (1993), Transplantation Proceeding Erythrocytosis", 25(1): pp. 1029-1031.	s, "Enalapril: Safe and Effective Therapy for Posttransplant			
xamine	r /Anish Gupta/	Date Considered 01/05/2007			
	21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. AG 36.	T.S. Kickler, et al., (1988), J. Am. Med. Assoc., "Effect of Erythropoietin Levels in Autologous Donors", 260; pp. 6. 21. Jaime Caro, et al., (1979), J. Lab. Clin. Med., "Erythropod 449-458. 22. Heinz W. Radtke, et al., (1979), Blood, "Serum Erythropod Degree of Anemia and Excretory Renal Function" 54(4): 23. Manju Chandra, M.D., et al., (1988), J. Pediatr., "Relatic Evidence for Lowered Set Point for Erythropoietin Productions for Nephrology" 11: pp. 203-209. 24. Joseph W. Eschbach, M.D., et al., (1988), American Jour Implications for Nephrology" 11: pp. 203-209. 25. Satya P. Kunapuli, et al., (1987), Circulation Research, for the Presence of Its mRNA in Rat Heart" 60: pp. 786-786-797. 26. W.M. Clouston, et al., (1988), Genomics, "Molecular Clouded CDNA Sequence", 23: pp. 3603-3609. 27. Ryoichiro Kageyama, et al., (1984), Biochemistry, "Princ Cloned cDNA Sequence", 23: pp. 3603-3609. 28. Hiroaki Ohkubo, et al., (1983), Biochemistry, "Cloning 2196-2200. 29. Dinna N. Cruz, M.D., et al., (1996), American Journal of Therapy in Chronic Hemodialysis Patients: Any Evidence of Anemia in Chronic Hemodialysis Patients: Any Evidence of Anemia in Chronic Hemodialysis Patients: Any Evidence of Anemia in Chronic Hemodialysis Patients ", 26: pp. 23-534. 31. Anne B. Gould, et al., (1980), J. Lab. Clin. Med., "Interestable of Anemia in Chronic Hemodialysis Patients", 26: pp. 23-534. 32. Peter J. Conlon, et al., (1993), Transplantation, "The Betransplantation", 56: pp. 217-219. 33. E.M. Anderson, et al., (1997), Biology of the Neonate, 71: pp. 194-197. 34. B.I. Shand, et al., (1995), Journal of Human Hypertens Elderly Patients with Essential Hypertension: A Pilot S. Erythrocytosis", 46: pp. 1397-1403. 36. R.S. Gaston, et al., (1993), Transplantation Proceeding Erythrocytosis", 46: pp. 1397-1403.			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

Form	PT	0.1	449

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Atty. Docket No.

98,009-B l

Serial No.

09/658,315

Applicant: Kathleen Rodgers, et al.

Filing Date: Sept 8, 2000

Group:

1653

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Lagger, 218					
A(1	M.S. Islam, et al., (1990), Transplant Int., "Captopril Induces Correction of Postrenal Transplant Erythremia", 3: pp. 222-225.			
1	1 1	Progenitors and Response to Enalapril", 26(1): pp. 280-2	Erythrocytosis After Renal Transplant: Study of Erythroid 81.		
†	39.	Michal Mrug, et al., (1997), The American Society for Clinical Investigation, Inc., "Angiotensin II Stimulates Proliferation of Normal Early Erythroid Progenitors", 100(9): pp. 2310-2314.			
1	40.	Fisher, et al., (1968), Annals New York Academy of Science Constriction on Erythropoietin Production", pp. 308-317	res, "Effects of Angiotensin, Norepinephrine and Renal Artery ".		
1	41.	James W. Fisher, et al., (1967), The Journal of Pharmacology and Experimental Therapeutics, "Effects of Angiotensin and			
1	42.	D.L. Mann, et al., (1966), P.S.E.B.M., "Effect of Renin, Angiotensin II and Aldosterone on Erythropoiesis", 121: pp. 1152-1154.			
4	43.	Yilmaz C. Bilsel, et al., (1963), P.S.E.B.M. "Angiotensin II and Erythropoiesis", 114: pp. 475-479.			
	44.	Ferrario, et al., (1998), J. Am. Soc. Nephrol., "Novel Angiotensin Peptides Regulate Blood Pressure, Endothelial Function, and Natriuresis", 9: pp. 1716-1722.			
	45.	Shridhar N. Iyer, et al., (1998), Hypertention, "Vasodepressor Actions of Angiotensin-(1-7) Unmasked During Combined Treatment with Lisinopril and Losartan", 31: pp. 699-705.			
	46.	Freeman, et al., (1996), Hypertension, "Angiotensin-(1-7) Inhibits Vascular Smooth Muscle Cell Growth", 28: page 104-108.			
	47.	Philipp Ambühl, et al., (1994), Brain Research Bulletin, "[7-D-ALA]-Angiotensin-(1-7): Selective Antagonism of Angiotensin-(1-7) in the Rat Paraventricular Nucleus", 35(4): pp. 289-291.			
	48.	Speth and Kim, (1990), BBRC, "Discrimination of Two Angiotensin II Receptor Subtypes with a Selective Agonist Analogo of Angiotensin II, p-Aminophenylalanine Angiotensin II", 169: pp. 997-1006.			
	49. Rose-Marie Catalioto, et al., (1994), European Journal of Pharmacology, "Angiotensins Induce the Release of Pr from Rabbit Vas Deferens: Evidence for Receptor Heterogeity", 256: pp. 93-97.		of Pharmacology, "Angiotensins Induce the Release of Prostacyclin ogeity", 256: pp. 93-97.		
_	50.	(1992) T			
Josef Pfeilschifter, et al., (1992), European Journal of Pharmacology-Molecular Pharmacology Section, Stimulation of Phospholipase D in Rat Renal Mesangial Cells is Mediated by the AT, Receptor Subtype'		harmacology-Molecular Pharmacology Section, "Angiotensin II Cells is Mediated by the AT, Receptor Subtype", 225: pp. 57-62.			
	52.	Neelam Jaiswal, et al., (1992), Hypertension, "Stimulation of Endothelial Cell Prostaglandin Production by Angiotensin Pentides", 19[suppl II]: pp. II-49 - II-55.			
١,	53.	Richard M. Edwards, et al., (1993), The Journal of Pharmacology and Experimental Therapeutics, "Angiotensin II Inhibit Glomerular Adenylate Cyclase via the Angiotensin II Receptor Subtype 1 (AT ₁)" 266(2): pp. 506-510.			
	AG 54.	Neelam Jaiswal, et al., (1993), The Journal of Pharmacology and Experimental Therapeutics, "Differential Regulation of Prostaglandin Synthesis by Angiotensin Peptides in Porcine Aortic Smooth Muscle Cells: Subtypes of Angiotensin Receptors Involved", 266(2): pp. 664-673.			
	Examiner	/Anish Gupta/	Date Considered 01/05/2007		

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office TION DISCLOSURE	Atty. Docket No. 98,009-B	Serial No.			
STATEME	STATEMENT BY APPLICANT		1.			
		Filing Date: Sept 8, 2000	Group: 1653			
OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.						
	OTHER DOCUMENTS MISSES IN Human					

L	OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.						
A	55.	Neelam Jaiswal, et al., (1991), Hypertension, "Subtype 2 Angiotensin Receptors Mediate Prostaglandin Synthesis in Human Astrocytes", 17: pp. 1115-1120.					
AG	Engoingitum, implications joi and the						
AG 57. Regoli, et al., (1974), Pharmacological Reviews, "Pharmacology of Angiotensin'", 26(2): pp. 69-123.		armacology of Angiotensin ¹ ", 26(2): pp. 69-123.					
Ex	aminer	/Anish Gupta/	Date Considered 01/05/2007				
		1 Halla	is in conformance with MPEP 609; Draw line through citation if				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.